Roche, one of the world’s largest international pharmaceuticals groups, has decided to abandon research on medicines to treat HIV in a significant blow to doctors treating the spiralling international Aids epidemic.

In a memo circulated this week to Aids specialists and activists, executives said because of disappointing results in clinical trials, the company had cancelled its programme for the compounds in development that were targeting two different ways to attack HIV.